194 related articles for article (PubMed ID: 37435448)
1. Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations.
Peverelli E; Treppiedi D; Mantovani G
Endocr Oncol; 2022 Jan; 2(1):R24-R30. PubMed ID: 37435448
[TBL] [Abstract][Full Text] [Related]
2. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro.
Albani A; Perez-Rivas LG; Tang S; Simon J; Lucia KE; Colón-Bolea P; Schopohl J; Roeber S; Buchfelder M; Rotermund R; Flitsch J; Thorsteinsdottir J; Herms J; Stalla G; Reincke M; Theodoropoulou M
Endocr Relat Cancer; 2022 Aug; 29(8):503-511. PubMed ID: 35686696
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
4. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
[TBL] [Abstract][Full Text] [Related]
5. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs.
Treppiedi D; Marra G; Di Muro G; Esposito E; Barbieri AM; Catalano R; Mangili F; Bravi F; Locatelli M; Lania AG; Ferrante E; Indirli R; Nozza E; Arlati F; Spada A; Arosio M; Mantovani G; Peverelli E
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626057
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
[TBL] [Abstract][Full Text] [Related]
8. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
9. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs.
Treppiedi D; Di Muro G; Marra G; Barbieri AM; Mangili F; Catalano R; Serban A; Ferrante E; Locatelli M; Lania AG; Arosio M; Spada A; Peverelli E; Mantovani G
Endocr Relat Cancer; 2021 Jun; 28(8):573-582. PubMed ID: 34086599
[TBL] [Abstract][Full Text] [Related]
10. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression.
Mizuno T; Inoshita N; Fukuhara N; Tatsushima K; Takeshita A; Yamada S; Nishioka H; Takeuchi Y
Intern Med; 2022 Mar; 61(5):679-685. PubMed ID: 34471015
[TBL] [Abstract][Full Text] [Related]
12. Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs.
Sato A; Hara Y
Res Vet Sci; 2018 Aug; 119():61-66. PubMed ID: 29864631
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas.
Cuevas-Ramos D; Fleseriu M
J Mol Endocrinol; 2014 Jun; 52(3):R223-40. PubMed ID: 24647046
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of β-arrestin1 and β-arrestin2 on somatostatin receptors in murine AtT-20 corticotroph tumor cells.
Kageyama K; Hagiwara R; Niioka K; Takayasu S; Daimon M
Endocr J; 2021 Feb; 68(2):163-170. PubMed ID: 32963176
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
16. Recurrent gain-of-function USP8 mutations in Cushing's disease.
Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
[TBL] [Abstract][Full Text] [Related]
17. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
18. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel
Treppiedi D; Barbieri AM; Di Muro G; Marra G; Mangili F; Catalano R; Esposito E; Ferrante E; Serban AL; Locatelli M; Lania AG; Spada A; Arosio M; Peverelli E; Mantovani G
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439178
[TBL] [Abstract][Full Text] [Related]
19. Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas.
Sbiera S; Tryfonidou MA; Weigand I; Grinwis GC; Broeckx B; Herterich S; Allolio B; Deutschbein T; Fassnacht M; Meij BP
PLoS One; 2016; 11(12):e0169009. PubMed ID: 28005997
[TBL] [Abstract][Full Text] [Related]
20. Somatic
Pérez-Rivas LG; Theodoropoulou M; Puar TH; Fazel J; Stieg MR; Ferraù F; Assié G; Gadelha MR; Deutschbein T; Fragoso MC; Kusters B; Saeger W; Honegger J; Buchfelder M; Korbonits M; Bertherat J; Stalla GK; Hermus AR; Beuschlein F; Reincke M
Eur J Endocrinol; 2018 Jan; 178(1):57-63. PubMed ID: 28982703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
